EGFR and non-small cell lung carcinoma: Multiple generations of oral EGFR tyrosine kinase inhibitors (TKIs) have been approved by the US Food and Drug Administration (FDA) for first-line therapy in those with EGFR-activating mutations in advanced NSCLC.